---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-041271"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2023-12-12T23:59:59+00:00"
generated_at: "2026-06-07T14:16:36.804615+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics enters license and collaboration agreement with Merck to develop degrader-antibody conjugates

## Summary
- C4T grants Merck worldwide exclusive license for DACs directed to an initial undisclosed oncology target.
- Merck pays $10 million upfront; C4T eligible for up to ~$600 million in milestones for initial target plus tiered royalties.
- Merck has options for three additional targets; if all exercised, total potential payments to C4T up to ~$2.5 billion.
- Collaboration leverages C4T's TORPEDO platform for degrader payloads and Merck's antibody conjugation expertise.
- Merck responsible for all development, regulatory, manufacturing, and commercialization costs.

## SEC filing metadata
- accession: 0001628280-23-041271
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2023-12-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828023041271/0001628280-23-041271-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828023041271/cccc-20231212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-041271
- JSON: https://secwatch.observer/filing/0001628280-23-041271.json
- Plain text: https://secwatch.observer/filing/0001628280-23-041271.txt

## Key facts
- Material Agreements
  C4 Therapeutics, Inc. entered into License Agreement with Merck Sharp & Dohme LLC valued at up to approximately $2.5 billion in potential payments across the entire collaboration (effective 2023-12-11).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Merck Sharp & Dohme LLC
  - Value: up to approximately $2.5 billion in potential payments across the entire collaboration
  - Effective: 2023-12-11
  source text: C4 Therapeutics, Inc. (“ C4T ”) entered into a License and Collaboration Agreement (“ License Agreement ”) with Merck Sharp & Dohme LLC (“ Merck ”) to collaborate on the development and commercialization of degrader-antibody conjugates ( “ DACs ”: ), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828023041271/0001628280-23-041271-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.